Alkermes plc stock (IE00B56GVS15): focus shifts after oncology spin-off and latest quarterly figures

Alkermes has sharpened its focus on neuroscience after spinning off its oncology business. Fresh quarterly numbers and updated 2025 guidance are now in focus for investors watching the Nasdaq-listed biotech specialist.

Alkermes plc reported first-quarter 2025 results and updated its full-year 2025 financial guidance in late April, underlining its transition to a pure-play neuroscience company following the spin-off of its oncology business into Mural Oncology in 2024, according to Alkermes investor update as of 04/24/2025. The company highlighted revenue growth from key psychiatric and addiction treatments and reiterated its focus on profitability after the portfolio reshaping, as detailed in the same earnings release and related materials on its investor site.

As of: 16.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Alkermes plc
• Sector/industry: Biopharmaceuticals, neuroscience
• Headquarters/country: Dublin, Ireland
• Core markets: United States and selected international markets for neuroscience and addiction therapies
• Key revenue drivers: Proprietary drugs for schizophrenia, bipolar I disorder and alcohol and opioid dependence, plus royalty income from partnered therapies
• Home exchange/listing venue: Nasdaq (ticker: ALKS)
• Trading currency: USD

Alkermes plc: core business model

Alkermes plc is a biopharmaceutical company focused on developing and commercializing medicines in the field of neuroscience, primarily targeting serious mental illness and addiction. The business model combines fully owned commercial products with partnered programs that generate royalties and milestones from larger pharmaceutical companies, according to the company description in its annual report published in February 2025 for fiscal year 2024 on the investor site Alkermes Form 10-K overview as of 02/22/2025.

The company’s strategy is to use its formulation technologies and clinical expertise to develop therapies that can improve adherence and outcomes in chronic psychiatric and addiction conditions. This approach is visible in long-acting injectable treatments and once-daily oral medications that aim to simplify dosing schedules, as discussed in the same 2024 annual filing and supporting product information on the corporate website. Alkermes seeks to balance internal development with collaborations in order to manage risk and leverage partners’ commercial scale, particularly in the United States.

Following the separation of its oncology pipeline into Mural Oncology in 2024, Alkermes now positions itself as a more focused neuroscience company, emphasizing cost discipline and margin expansion alongside continued investment in research and development. Management has highlighted that this streamlined portfolio should allow capital allocation to be concentrated on late-stage neuroscience assets and commercial execution, as noted in the company’s 2025 earnings commentary and strategy update presented with the first-quarter 2025 results, according to Alkermes separation announcement as of 11/15/2024.

Main revenue and product drivers for Alkermes plc

Alkermes generates revenue from a portfolio that includes proprietary commercial products and royalty-bearing collaborations. Key fully owned products include LYBALVI, an oral treatment for adults with schizophrenia or bipolar I disorder, and VIVITROL, an injectable medication indicated for alcohol dependence and for prevention of relapse to opioid dependence after detoxification. According to the company’s 2024 annual report published in February 2025, these two brands accounted for a substantial portion of net product sales in 2024, reflecting Alkermes’ focus on central nervous system disorders.

On the partnered side, Alkermes earns royalties on sales of drugs such as INVEGA SUSTENNA and INVEGA TRINZA, long-acting injectable antipsychotics commercialized by Janssen, a Johnson & Johnson company. The royalty streams arise from the company’s contribution to formulation technologies and intellectual property embedded in these therapies, as outlined in detail in the royalty and collaboration section of the 2024 Form 10-K filed in February 2025. These agreements allow Alkermes to participate in global sales trends in serious mental illness without bearing the full cost of worldwide commercialization.

The company also records contract revenue from licensing arrangements and milestones tied to the progress or commercial performance of partnered programs. Over time, management has emphasized that a growing share of revenue should come from its proprietary portfolio, particularly LYBALVI, which launched in the United States in 2021 and has since expanded its prescriber base. According to comments in the first-quarter 2025 earnings release dated April 24, 2025, Alkermes reported continued growth in LYBALVI net sales compared with the prior-year period and highlighted this product as a central pillar of its mid-term growth algorithm Alkermes investor update as of 04/24/2025.

Conclusion

Alkermes plc has undergone a notable strategic shift by separating its oncology business and sharpening its focus on neuroscience and addiction treatments, with recent quarterly results and updated 2025 guidance providing a fresh snapshot of progress. The company’s revenue mix of proprietary drugs and royalty-bearing collaborations offers multiple income streams, while management has signaled an emphasis on profitability and disciplined capital allocation after the portfolio reshaping. For US-focused investors following Nasdaq-listed biotech names, Alkermes represents a mid-cap player anchored in serious mental illness and addiction markets, where long-term demand is influenced by demographic, societal and healthcare system trends. As with all biopharmaceutical stocks, the investment profile remains sensitive to clinical outcomes, regulatory developments, payer dynamics and competitive launches in core therapeutic areas.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.